HMOX1 and neoplasm: Through inhibiting the expression of HO-1 downstream of Nrf2, metformin attenuates the proliferation of tumor cells and enhancing their sensitivity to anticancer drugs, indicating that the Raf/ERK/Nrf2 axis is a new molecular target for CC therapy (110).